Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK Cell Therapy for Severe Endometriosis
NCT03948828Phase 1Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of troculeucel in endometriosis (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 3 months and Purity and Function of NK cells. Status: unknown.
02
Drugs
troculeucel
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03948828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948828.